Predict your next investment

Cerevast Therapeutics company logo
HEALTHCARE | Medical Devices & Equipment / Therapeutic Devices
cerevast.com

See what CB Insights has to offer

Founded Year

2009

Stage

Series D | Alive

Total Raised

$23.32M

Last Raised

$10M | 7 yrs ago

About Cerevast Therapeutics

Cerevast Therapeutics is developing a non-invasive treatment for acute ischemic stroke known as sonothrombolysis, or SonoLysis for short. This treatment harnesses the acoustic energy from externally applied ultrasound to treat stroke-causing clots in the blood vessels of the brain. The company has developed an operator-independent ultrasonic headframe called the ClotBust-ER. This device can be rapidly and easily deployed by virtually any emergency room staff to safely administer the ultrasound energy for SonoLysis therapy.

Cerevast Therapeutics Headquarter Location

11601 Willows Road Suite 100

Redmond, Washington, 98052,

United States

425-821-1603

Latest Cerevast Therapeutics News

BIO Elects New Board Officers and Members

Jun 7, 2016

June 06, 2016 09:00 PM Eastern Daylight Time SAN FRANCISCO--( BUSINESS WIRE )--The Biotechnology Innovation Organization  (BIO) is pleased to announce the election of two new Board Officers, several new Section Governing Board Chairs, and 21 new members of its Board of Directors, all voted upon at this year’s 2016 BIO International Convention. Bradford Zakes, Chief Executive Officer, Cerevast Therapeutics, was elected to serve as BIO’s Board Treasurer; and David Meeker, Chief Executive Officer, Genzyme/Sanofi, was elected to serve as Board Secretary. Ron Cohen, President & CEO, Acorda Therapeutics, was re-elected to another term as Chair. In addition, BIO announces the election of Alan Shaw, President & CEO, Calysta, as the new Chair of the Industrial & Environmental Section Governing Board; Michael Narachi, President & CEO, Orexigen Therapeutics, as the new Chair of the Emerging Companies Section Governing Board; and Eddie Sullivan, President & CEO, SAB Biotherapeutics, as the new Chair of the Food & Agriculture Section Governing Board. “We welcome our new officers, Board leaders, and Board Members, and are looking forward to working with them to create a more favorable policy, legislative, and business development environment for the global biotech industry,” said Jim Greenwood, BIO President & CEO. “This newly-constituted Board of Directors brings significant industry experience and passion that will serve BIO and its members well.” Greenwood also thanked BIO’s departing Board Members, saying, “BIO is deeply appreciative to departing Board Members for their dedication and commitment over the years.” BIO’s Board also elected a new slate of Executive Committee members for the 2016-2017 term. They are: Ron Cohen, President & CEO, Acorda Therapeutics – Board/Health Section Chair Bradford Zakes, Chief Executive Officer, Cerevast Therapeutics – Board Treasurer David Meeker, Chief Executive Officer, Genzyme/Sanofi – Board Secretary Paul Hastings, President & CEO, OncoMed Pharmaceuticals – Health Section Vice Chair Alan Shaw, President & CEO, Calysta – Industrial & Environmental Section (IES) Governing Board Chair Tjerk de Ruiter, Chief Executive Officer, Corbian – IES Vice Chair Michael Narachi, President & CEO, Orexigen Therapeutics – Emerging Companies Section (ECS) Governing Board Chair Eddie Sullivan, President & CEO, SAB Biotherapeutics – Food & Agriculture Section (FAS) Governing Board Chair Philip Miller, Vice President Global Regulatory and Government Affairs, Monsanto – Food & Agriculture Section (FAS) Governing Board Vice Chair Rachel King, Chief Executive Officer, GlycoMimetics – Immediate Past Chair Alex Azar, President of Lilly USA, Eli Lilly and Company – At-Large Ian Clark, CEO & Head of North American Commercial Operations, Genentech/Roche – At-Large Doug Doerfler, President & CEO, MaxCyte – At-Large Julie Gerberding, Executive Vice President for Strategic Communications, Global Public Policy & Population Health, Merck – At-Large Perry Karsen, Chairman & CEO, Jounce Therapeutics – At-Large John Maraganore, Chief Executive Officer, Alnylam Pharmaceuticals – At-Large Richard Pops, Chairman & CEO, Alkermes – At-Large Jay Siegel, Chief Biotechnology Officer & Head of Scientific Strategy & Policy, Johnson & Johnson – At-Large The full BIO Board of Directors is comprised of the elected Directors serving on each of BIO’s Section Governing Boards. The newly-elected Board Members from these Sections are: Emerging Companies Section Governing Board Julie Smith, President & CEO, Raptor Pharmaceuticals Steven Paul, President & CEO, Voyager Therapeutics Food & Agriculture Section Governing Board Brian Barker, General Manager, US Seeds, Dow AgroSciences Rick Van Genderen, Director, Business Management, BASF Plant Science, BASF Health Section Governing Board Albert Bourla, Group President of Global Innovative Pharma and Global Vaccines, Oncology and Consumer Healthcare Business, Pfizer Habib Dable, President, U.S. Pharmaceuticals, Bayer Mark Enyedy, President & CEO, ImmunoGen Bill Hinshaw, Executive Vice President and Head, US, Novartis Oncology Joe LaRosa, Senior Vice President, General Counsel and Secretary, Regeneron Jeremy Levin, Chairman of the Board & CEO, Ovid Therapeutics Kiran Mazumdar-Shaw, Chairperson and Managing Director, Biocon Limited David Nicholson, Chief R&D Officer, Allergan James Sapirstein, Chief Executive Officer, ContraVir Julie Smith, President & CEO, Raptor Pharmaceuticals Kathleen Tregoning, Senior Vice President, Corporate Affairs, Biogen Neil Warma, President & CEO, Opexa Therapeutics Industrial & Environmental Section Governing Board Jennifer Holmgren, Chief Executive Officer, LanzaTech John Melo, President & CEO, Amyris About BIO BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention , the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter . Upcoming BIO Events

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cerevast Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cerevast Therapeutics is included in 2 Expert Collections, including Neuroscience.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

M

Medical Devices

7,401 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. Excludes CDMOs/CMOs. *Columns updated as regularly as possible.

Cerevast Therapeutics Patents

Cerevast Therapeutics has filed 5 patents.

The 3 most popular patent topics include:

  • Acoustics
  • Ion channels
  • Membrane biology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/5/2017

8/27/2019

Ion channels, Neurophysiology, Membrane biology, Neurotechnology, Acoustics

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

7/5/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

8/27/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Ion channels, Neurophysiology, Membrane biology, Neurotechnology, Acoustics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Cerevast Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cerevast Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.